US 12,168,685 B2
Phage-displayed accessible recombinant targeted antibodies and methods of making same
Renata Pasqualini, New Brunswick, NJ (US); Wadih Arap, New Brunswick, NJ (US); Fernanda Iamassaki Staquicini, New Brunswick, NJ (US); Fortunato Ferrara, Santa Fe, NM (US); Sara D'Angelo, Santa Fe, NM (US); and Andrew R. M. Bradbury, Santa Fe, NM (US)
Assigned to RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY, New Brunswick, NJ (US)
Filed by Rutgers, The State University of New Jersey, New Brunswick, NJ (US)
Filed on Oct. 18, 2022, as Appl. No. 18/047,533.
Application 18/047,533 is a division of application No. 17/592,828, filed on Feb. 4, 2022.
Application 17/592,828 is a division of application No. 16/333,898, granted, now 11,254,751, issued on Feb. 22, 2022, previously published as PCT/US2017/052661, filed on Sep. 21, 2017.
Claims priority of provisional application 62/397,521, filed on Sep. 21, 2016.
Claims priority of provisional application 62/397,512, filed on Sep. 21, 2016.
Prior Publication US 2023/0139913 A1, May 4, 2023
Int. Cl. C07K 16/18 (2006.01); A61K 38/07 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 47/68 (2017.01); A61K 49/00 (2006.01); A61P 35/00 (2006.01); C07K 14/47 (2006.01); C07K 16/00 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C12N 15/10 (2006.01); C12N 15/64 (2006.01); C12Q 1/6869 (2018.01); G01N 33/50 (2006.01); G01N 33/574 (2006.01)
CPC C07K 16/18 (2013.01) [A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); A61K 47/6803 (2017.08); A61K 47/68031 (2023.08); A61K 47/68033 (2023.08); A61P 35/00 (2018.01); C07K 16/30 (2013.01); C07K 16/3023 (2013.01); G01N 33/574 (2013.01); A61K 38/07 (2013.01); A61K 2039/505 (2013.01); A61K 47/6817 (2017.08); A61K 47/6843 (2017.08); A61K 47/6849 (2017.08); A61K 47/6891 (2017.08); A61K 49/0008 (2013.01); C07K 14/47 (2013.01); C07K 16/005 (2013.01); C07K 16/28 (2013.01); C07K 16/2866 (2013.01); C07K 2317/21 (2013.01); C07K 2317/35 (2013.01); C07K 2317/55 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2317/77 (2013.01); C12N 15/1037 (2013.01); C12N 15/64 (2013.01); C12N 2810/00 (2013.01); C12Q 1/6869 (2013.01); G01N 33/5011 (2013.01); G01N 33/57423 (2013.01)] 18 Claims
OG exemplary drawing
 
1. A method for selecting antibody binding fragments that home to a tumor in vivo in a mammalian host, the method comprising:
a) screening a phage display library against at least one known tumor target to generate an enriched multivalent phage display library;
b) introducing phage particles from the enriched multivalent phage display library into a live mammalian host, wherein the mammalian host bears at least one tumor;
c) allowing the phage particles to home to the at least one tumor;
d) harvesting tumor tissue from the at least one tumor in the mammalian host;
e) extracting DNA from the tumor tissue;
f) isolating from the extracted DNA phage particles displaying antibody binding fragments that have bound to the tumor tissue in vivo; and
g) identifying the antibody binding fragments in the isolated phage particles.